bioworld.com

Tandem’s Control-IQ+ looks like a smart move for insulin-using T2D

Tandem Diabetes Care Inc.’s Control-IQ+ automated insulin delivery system improved multiple measures of glycemic control in individuals with type 2 diabetes who use insulin, a study presented March 19 at the 18th International Conference on Advanced Technologies & Treatments for Diabetes and published in The New England Journal of Medicine demonstrated.

BioWorld MedTechClinicalDiabetesContinuous glucose monitor (CGM)

Read full news in source page